1. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
- Author
-
Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, Parving HH, and Vaag AA
- Subjects
- Blood Glucose metabolism, Carbamates adverse effects, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin adverse effects, Glycated Hemoglobin metabolism, Humans, Hypoglycemia chemically induced, Hypoglycemia prevention & control, Hypoglycemic Agents adverse effects, Insulin administration & dosage, Insulin adverse effects, Insulin Aspart, Male, Metformin adverse effects, Middle Aged, Patient Compliance, Piperidines adverse effects, Treatment Outcome, Weight Gain, Carbamates administration & dosage, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents administration & dosage, Insulin analogs & derivatives, Metformin administration & dosage, Piperidines administration & dosage
- Abstract
Objectives: To study the effect of insulin treatment in combination with metformin or an insulin secretagogue, repaglinide, on glycaemic regulation in non-obese patients with type 2 diabetes., Design: Randomised, double blind, double dummy, parallel trial., Setting: Secondary care in Denmark between 2003 and 2006., Participants: Non-obese patients (BMI
- Published
- 2009
- Full Text
- View/download PDF